Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety
Details
Serval ID
serval:BIB_E2DB607A5C0C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety
Journal
American Journal of Obstetrics and Gynecology
ISSN
0002-9378
Publication state
Published
Issued date
07/2003
Peer-reviewed
Oui
Volume
189
Number
1
Pages
55-8
Notes
Clinical Trial
Journal Article
Randomized Controlled Trial --- Old month value: Jul
Journal Article
Randomized Controlled Trial --- Old month value: Jul
Abstract
OBJECTIVE: The purpose of this study was to investigate whether the effects of 17beta-estradiol tablets that are designed for the treatment of postmenopausal urovaginal atrophy are influenced by the site of placement into the vagina. STUDY DESIGN: In this controlled crossover trial, 10 postmenopausal women received a single 17beta-estradiol tablet in the outer or inner one third of the vagina. Before and 3 hours after treatment, the pulsatility index, resistance index, and blood flow were evaluated in the uterine and periurethral vessels by Doppler examination. Parallel 17beta-estradiol serum evaluations were performed. RESULTS: Comparable and significant increases in 17beta-estradiol were observed. After inner administration, the pulsatility index and resistance index of both uterine arteries decreased; uterine artery blood flow increased significantly (P <.0001) but decreased in periurethral vessels (P <.02). After outer administration, the uterine artery pulsatility index, resistance index, and blood flow did not change, and the periurethral blood flow significantly increased (P <.0001). CONCLUSION: For optimizing the efficacy while minimizing the risk of endometrial hyperplasia, 17beta-estradiol tablets must be placed in the outer one third of the vagina.
Keywords
Administration, Intravaginal
Cross-Over Studies
Estradiol/*administration & dosage/blood
Female
Follicle Stimulating Hormone/blood
Humans
Middle Aged
*Postmenopause
Pulsatile Flow
Urethra/*drug effects
Uterus/blood supply/*drug effects
Vagina/*drug effects
Vascular Resistance
Pubmed
Web of science
Create date
28/02/2008 11:37
Last modification date
20/08/2019 16:06